[{"id":"10310321-528e-4d9c-ac69-c830431aed02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03760081","created_at":"2021-01-18T18:28:48.728Z","updated_at":"2024-07-02T16:36:19.923Z","phase":"Phase 2","brief_title":"A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors","source_id_and_acronym":"NCT03760081","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • ASP1650"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 03/19/2019","start_date":" 03/19/2019","primary_txt":" Primary completion: 10/16/2020","primary_completion_date":" 10/16/2020","study_txt":" Completion: 10/16/2020","study_completion_date":" 10/16/2020","last_update_posted":"2021-12-02"},{"id":"d4348c92-ba91-4010-b00b-89b84a2de82c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02054351","created_at":"2021-01-18T09:26:50.599Z","updated_at":"2024-07-02T16:36:20.880Z","phase":"Phase 1","brief_title":"Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)","source_id_and_acronym":"NCT02054351","lead_sponsor":"Ganymed Pharmaceuticals GmbH","biomarkers":" MUC16 • CLDN6","pipe":"","alterations":" ","tags":["MUC16 • CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP1650"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/06/2014","start_date":" 02/06/2014","primary_txt":" Primary completion: 10/28/2015","primary_completion_date":" 10/28/2015","study_txt":" Completion: 10/28/2015","study_completion_date":" 10/28/2015","last_update_posted":"2021-11-10"}]